Emerging research indicates that
azelastine nasal spray
, a common over-the-counter antihistamine, might offer a surprising benefit: reducing the risk of COVID-19 and common cold infections. A recent mid-stage trial conducted by German researchers and published in JAMA Internal Medicine suggests this accessible treatment could complement existing preventive strategies. This is an exciting development for public health. [1, 2]
Trial Highlights: Azelastine Nasal Spray Efficacy
The randomized clinical trial involved 450 volunteers, split into two groups. Participants either used an azelastine nasal spray, typically prescribed for allergy symptoms, or a placebo spray three times daily for 56 days. The findings revealed a substantial difference in infection rates between the groups. [1, 5, 9]
During the observation period, only 2.2% of individuals in the azelastine group contracted COVID-19, in contrast to 6.7% in the placebo group. This represents a two-thirds reduction in SARS-CoV-2 infections. Furthermore, the azelastine group experienced fewer symptomatic COVID-19 cases and a reduced incidence of rhinovirus infections, the primary cause of common colds. Specifically, 1.8% of the treatment group developed a rhinovirus infection compared to 6.3% in the placebo group. [1, 5, 9]
Understanding the Antiviral Action of Azelastine
Azelastine has been available for decades, primarily for treating seasonal allergies. However, previous in vitro studies suggested it possessed antiviral properties against SARS-CoV-2 and other respiratory viruses. The exact mechanism of action for
azelastine nasal spray
‘s antiviral effects is likely multifaceted. Researchers propose that it may interfere with viral entry by interacting with ACE2 receptors, inhibit key enzymes necessary for viral replication, and stabilize the epithelial barrier in the nasal mucosa. Additionally, it can suppress ICAM-1, a crucial receptor for rhinoviruses. These mechanisms collectively reduce the chance of successful viral replication and spread at the initial entry point. [2, 3, 8, 11]
Future Implications for Prevention
The results of this trial present a promising outlook for azelastine nasal spray as an easily accessible prophylactic tool. Professor Robert Bals of Saarland University Medical Center, the study leader, emphasized that if further research validates these findings, azelastine could enhance protective measures. This is particularly relevant for vulnerable populations, during periods of high infection rates, or for individuals undertaking travel. However, larger, multicenter trials are necessary to confirm these effects across diverse populations and to explore its full potential against various respiratory pathogens. Experts also advise that azelastine should supplement, not replace, established hygiene practices and COVID-19 vaccines. [1, 4, 6, 7]
Frequently Asked Questions
Q1: What is azelastine nasal spray?
Azelastine nasal spray is an over-the-counter antihistamine commonly used to alleviate symptoms associated with seasonal allergies, such as sneezing, itching, and nasal congestion. [2, 6]
Q2: How effective was azelastine nasal spray in preventing COVID-19 and common colds in the trial?
In the mid-stage trial, azelastine nasal spray reduced COVID-19 infections by two-thirds (2.2% in the azelastine group vs. 6.7% in the placebo group). It also significantly reduced rhinovirus infections, the cause of common colds (1.8% vs. 6.3%). [1, 5]
Q3: Can azelastine nasal spray replace current COVID-19 prevention methods?
No, researchers and experts stress that while promising, azelastine nasal spray should serve as an additional prophylactic measure. It complements existing protective strategies like vaccination and good hygiene, but it does not replace them. [1, 7, 11]
References
- Nasal spray for allergies may help prevent COVID, common cold infections – ETHealthworld
- Azelastine Nasal Spray Reduces SARS-CoV-2 Infections in Phase 2 Trial – Contagion Live
- Antiviral Potential of Azelastine against Major Respiratory Viruses – PMC
- COVID-19 infection risk cut ‘significantly’ with simple nasal spray, research finds – Fox News
- Antihistamine nasal spray prevents COVID-19, study finds – CIDRAP
- Common allergy spray slashes COVID-19 risk in surprising trial – ScienceDaily
- Why a Common Allergy Nasal Spray Might Prevent COVID – WebMD
- Azelastine Nasal Spray Shows Promise in Preventing COVID-19 Infections in Clinical Trial
- New study finds over-the-counter treatment could help prevent COVID | The Independent
- Azelastine is effective against the major variants of concerns in… – ResearchGate
- Why a common allergy nasal spray might prevent COVID | University of Cincinnati
- Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial – PMC
- This over-the-counter spray could protect you from COVID-19: study | KTVU FOX 2
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.